1
|
Pöstges F, Lenhart J, Stoyanov E, Lunter DJ, Wagner KG. Phase homogeneity in ternary amorphous solid dispersions and its impact on solubility, dissolution and supersaturation - Influence of processing and hydroxypropyl cellulose grade. Int J Pharm X 2023; 6:100222. [PMID: 38162398 PMCID: PMC10755049 DOI: 10.1016/j.ijpx.2023.100222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2023] [Revised: 11/13/2023] [Accepted: 12/01/2023] [Indexed: 01/03/2024] Open
Abstract
As performance of ternary amorphous solid dispersions (ASDs) depends on the solid-state characteristics and polymer mixing, a comprehensive understanding of synergistic interactions between the polymers in regard of dissolution enhancement of poorly soluble drugs and subsequent supersaturation stabilization is necessary. By choosing hot-melt extrusion (HME) and vacuum compression molding (VCM) as preparation techniques, we manipulated the phase behavior of ternary efavirenz (EFV) ASDs, comprising of either hydroxypropyl cellulose (HPC)-SSL or HPC-UL in combination with Eudragit® L 100-55 (EL 100-55) (50:50 polymer ratio), leading to single-phased (HME) and heterogeneous ASDs (VCM). Due to higher kinetic solid-state solubility of EFV in HPC polymers compared to EL 100-55, we visualized higher drug distribution into HPC-rich phases of the phase-separated ternary VCM ASDs via confocal Raman microscopy. Additionally, we observed differences in the extent of phase-separation in dependence on the selected HPC grade. As HPC-UL exhibited decisive lower melt viscosity than HPC-SSL, formation of partially miscible phases between HPC-UL and EL 100-55 was facilitated. Consequently, as homogeneously mixed polymer phases were required for optimal extent of solubility improvement, the manufacturing-dependent differences in dissolution performances were smaller using HPC-UL, instead of HPC-SSL, i.e. using HPC-UL was less demanding on shear stress provided by the process.
Collapse
Affiliation(s)
- Florian Pöstges
- Department of Pharmaceutical Technology and Biopharmaceutics, University of Bonn, Gerhard-Domagk-Str. 3, 53121 Bonn, Germany
| | - Jonas Lenhart
- Department of Pharmaceutical Technology, Faculty of Sciences, University of Tübingen, Auf d. Morgenstelle 8, 72076 Tübingen, Germany
| | - Edmont Stoyanov
- Nisso Chemical Europe GmbH, Berliner Allee 42, 40212 Düsseldorf, Germany
| | - Dominique J. Lunter
- Department of Pharmaceutical Technology, Faculty of Sciences, University of Tübingen, Auf d. Morgenstelle 8, 72076 Tübingen, Germany
| | - Karl G. Wagner
- Department of Pharmaceutical Technology and Biopharmaceutics, University of Bonn, Gerhard-Domagk-Str. 3, 53121 Bonn, Germany
| |
Collapse
|
2
|
Nyamba I, Jennotte O, Sombie CB, Lechanteur A, Sacre PY, Djande A, Semde R, Evrard B. Preformulation study for the selection of a suitable polymer for the development of ellagic acid-based solid dispersion using hot-melt extrusion. Int J Pharm 2023:123088. [PMID: 37257795 DOI: 10.1016/j.ijpharm.2023.123088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2022] [Revised: 05/22/2023] [Accepted: 05/25/2023] [Indexed: 06/02/2023]
Abstract
Ellagic acid is one of the most studied polyphenolic compounds due to its numerous promising therapeutic properties. However, this therapeutic potential remains difficult to exploit owing to its low solubility and low permeability, resulting in low oral bioavailability. In order to allow an effective therapeutic application of EA, it is therefore necessary to develop strategies that sufficiently enhance its solubility, dissolution rate and bioavailability. For this purpose, solid dispersions based on pre-selected polymers such as Eudragit® EPO, Soluplus® and Kollidon® VA 64, with 5% w/w ellagic acid loading were prepared by hot extrusion and characterized by X-ray diffraction, FTIR spectroscopy and in vitro dissolution tests in order to select the most suitable polymer for future investigations. The results showed that Eudragit® EPO was the most promising polymer for ellagic acid solid dispersions development because its extrudates allowed to obtain a solution supersaturated in ellagic acid that was stable for at least 90 min. Moreover, the resulting apparent solubility was 20 times higher than the actual solubility of ellagic acid. The extrudates also showed a high dissolution rate of ellagic acid (96.25% in 15 min), compared to the corresponding physical mixture (6.52% in 15 min) or the pure drug (1.56% in 15 min). Furthermore, increasing the loading rate of ellagic acid up to 12% in extrudates based on this polymer did not negatively influence its release profile through dissolution tests.
Collapse
Affiliation(s)
- Isaïe Nyamba
- Laboratory of Pharmaceutical Technology and Biopharmacy, Center for Interdisciplinary Research on Medicines (CIRM), Université de Liège, 4000 Liège (Belgium); Laboratory of Drug Development, Center of training, research and expertise in pharmaceutical sciences (CFOREM), Doctoral School of Sciences and Health, Université Joseph KI-ZERBO, 03 BP 7021 Ouagadougou 03 (Burkina Faso).
| | - Olivier Jennotte
- Laboratory of Pharmaceutical Technology and Biopharmacy, Center for Interdisciplinary Research on Medicines (CIRM), Université de Liège, 4000 Liège (Belgium)
| | - Charles B Sombie
- Laboratory of Drug Development, Center of training, research and expertise in pharmaceutical sciences (CFOREM), Doctoral School of Sciences and Health, Université Joseph KI-ZERBO, 03 BP 7021 Ouagadougou 03 (Burkina Faso)
| | - Anna Lechanteur
- Laboratory of Pharmaceutical Technology and Biopharmacy, Center for Interdisciplinary Research on Medicines (CIRM), Université de Liège, 4000 Liège (Belgium)
| | - Pierre-Yves Sacre
- Laboratory of Pharmaceutical Analytical Chemistry, Department of Pharmacy, Center for Interdisciplinary Research on Medicines (CIRM), University of Liege, 4000 Liege, Belgium
| | - Abdoulaye Djande
- Department of Chemistry, Laboratory of Molecular Chemistry and Materials, Research Team: Organic Chemistry and Phytochemistry, Université Joseph KI-ZERBO, 03 BP 7021 Ouagadougou 03 (Burkina Faso)
| | - Rasmané Semde
- Laboratory of Drug Development, Center of training, research and expertise in pharmaceutical sciences (CFOREM), Doctoral School of Sciences and Health, Université Joseph KI-ZERBO, 03 BP 7021 Ouagadougou 03 (Burkina Faso)
| | - Brigitte Evrard
- Laboratory of Pharmaceutical Technology and Biopharmacy, Center for Interdisciplinary Research on Medicines (CIRM), Université de Liège, 4000 Liège (Belgium)
| |
Collapse
|
3
|
Sasanam S, Thumthanaruk B, Wijuntamook S, Rattananupap V, Vatanyoopaisarn S, Puttanlek C, Uttapap D, Mussatto SI, Rungsardthong V. Extrusion of process flavorings from methionine and dextrose using modified starch as a carrier. PLoS One 2023; 18:e0269857. [PMID: 36735671 PMCID: PMC9897556 DOI: 10.1371/journal.pone.0269857] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2021] [Accepted: 05/27/2022] [Indexed: 02/04/2023] Open
Abstract
This study aimed to produce process flavorings from methionine and glucose via Maillard reaction by extrusion method. Modified starch was used as a carrier to reduce the torque and facilitate the production process. Five formulations of process flavorings with different ratios of methionine: dextrose: modified starch: water as MS5 (72:18:5:5), MS15 (64:16:15:5), MS25 (56:14:25:5), MS35 (42:12:35:5), and MS45 (40:10:45:5) were prepared and feded into the extruder. The temperatures of the extruder barrel in zones 1 and 2 were controlled at 100, and 120°C, with a screw speed of 30 rpm. The appearance of the obtained products, torque, pH before and after extrusion, color, volatile compounds, and sensory evaluation were determined. The extrudate from the formulation containing the highest amount of modified starch (MS45) gave the highest L* (lightness) of 88.00, which increased to 93.00 (very light) after grinding into a powder. The process flavorings from all formulations exhibited similar sensory scores in terms of aroma, taste, and water solubility, with a very slight difference in color. However, MS25, MS35 and MS45 indicated the torque at 10 Nm/cm3, while MS5 and MS 15 exhibited higher torque at 18, and 25 Nm/cm3, respectively. Extruded process flavorings from MS25 were analyzed for their flavor profiles by gas chromatography-mass spectrometry. Twelve volatile compounds including the key volatile compounds for sulfurous and vegetable odor type, dimethyl disulfide, methional, and methanethiol, were found. Four pyrazine compounds presented nutty, musty and caramelly odor; and 3-hydroxybutan-2-one and heptane-2,3-dione, which gave buttery odor type, were also detected. The results demonstrated a successful production of process flavorings using modified starch as carrier to facilitate and reduce the torque during the extrusion process.
Collapse
Affiliation(s)
- Sirinapa Sasanam
- Department of Agro-Industrial, Food and Environmental Technology, Faculty of Applied Science, Food and Agro-Industrial Research Center, King Mongkut’s University of Technology North Bangkok, Bangsue, Bangkok, Thailand
| | - Benjawan Thumthanaruk
- Department of Agro-Industrial, Food and Environmental Technology, Faculty of Applied Science, Food and Agro-Industrial Research Center, King Mongkut’s University of Technology North Bangkok, Bangsue, Bangkok, Thailand
| | | | | | - Savitri Vatanyoopaisarn
- Department of Agro-Industrial, Food and Environmental Technology, Faculty of Applied Science, Food and Agro-Industrial Research Center, King Mongkut’s University of Technology North Bangkok, Bangsue, Bangkok, Thailand
| | - Chureerat Puttanlek
- Department of Biotechnology, Faculty of Engineering and Industrial Technology, Silpakorn University, Nakhon Pathom, Thailand
| | - Dudsadee Uttapap
- Division of Biochemical Technology, School of Bioresources and Technology, King Mongkut’s University of Technology Thonburi, Bangkhuntian, Bangkok, Thailand
| | - Solange I. Mussatto
- Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark
| | - Vilai Rungsardthong
- Department of Agro-Industrial, Food and Environmental Technology, Faculty of Applied Science, Food and Agro-Industrial Research Center, King Mongkut’s University of Technology North Bangkok, Bangsue, Bangkok, Thailand
- * E-mail:
| |
Collapse
|
4
|
Althobaiti AA, Ashour EA, Almotairy A, Almutairi M, AlYahya M, Repka MA. Development and Characterization of Different Dosage Forms of Nifedipine/Indomethacin Fixed-Dose Combinations. J Drug Deliv Sci Technol 2023; 80:104117. [PMID: 36741268 PMCID: PMC9897319 DOI: 10.1016/j.jddst.2022.104117] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Studies have shown that 40 individuals out of 100,000 are diagnosed with rheumatoid arthritis (RA) yearly, with a total of 1.3 million in the United States. Furthermore, the impact of RA in some cases can extend to cardiovascular diseases (CVD), as the studies showed that 84% of RA patients are at risk of developing hypertension. This study aims to design and develop different dosage forms (capsule-in-capsule and three-dimensional (3D) printed tablet) of nifedipine/indomethacin fixed-dose combination (FDC). The hot-melt extrusion (HME) was utilized alone and with fused deposition modeling (FDM) techniques The developed dosage forms were intended to provide delayed-extended and immediate release profiles for indomethacin and nifedipine, respectively. FDC dosage forms were successfully developed and characterized. Nifedipine formulations showed significant improvement in release profiles, having 94% of the drug release at 30 minutes compared with pure nifedipine, which had a percent release of 2%. Furthermore, the release of indomethacin was successfully delayed at a pH of 1.2 and extended at a pH of 6.8. Differential scanning calorimetry results showed endothermic crystalline peaks at 165 °C and 176 °C for indomethacin and nifedipine, respectively. Moreover, the thermal analysis of all formulations showed the absence of the endothermic peaks indicating complete solubilization of indomethacin and nifedipine in the polymeric carriers. All formulations had post-processing drug content in the range of 95% to 98%. Moreover, results from the stability study showed that all formulations were able to remain chemically and physically stable with no signs of recrystallization or degradation. The designed FDC dosage forms could improve the quality of life by enhancing patient compliance and preventing the need for polypharmacy.
Collapse
Affiliation(s)
- Abdulmajeed A. Althobaiti
- Department of Pharmaceutics and Drug Delivery, University of Mississippi, School of Pharmacy, MS 38677
| | - Eman A. Ashour
- Department of Pharmaceutics and Drug Delivery, University of Mississippi, School of Pharmacy, MS 38677
| | - Ahmed Almotairy
- Department of Pharmaceutics and Drug Delivery, University of Mississippi, School of Pharmacy, MS 38677
- Pharmaceutics and Pharmaceutical Technology Department, College of Pharmacy Taibah University, Al Madinah AlMunawarah, 30001, Saudi Arabia
| | - Mashan Almutairi
- Department of Pharmaceutics and Drug Delivery, University of Mississippi, School of Pharmacy, MS 38677
- Department of Pharmaceutics, College of Pharmacy, University of Hail, Hail, 81442, Saudi Arabia
| | - Mohammed AlYahya
- Department of Pharmaceutics and Drug Delivery, University of Mississippi, School of Pharmacy, MS 38677
- Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia
| | - Michael A. Repka
- Department of Pharmaceutics and Drug Delivery, University of Mississippi, School of Pharmacy, MS 38677
- Pii Center for Pharmaceutical Technology, The University of Mississippi, University, MS 38677
| |
Collapse
|
5
|
Ren X, Liu Y, Fan C, Hong H, Wu W, Zhang W, Wang Y. Production, Processing, and Protection of Microalgal n-3 PUFA-Rich Oil. Foods 2022; 11:foods11091215. [PMID: 35563938 PMCID: PMC9101592 DOI: 10.3390/foods11091215] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2022] [Revised: 04/15/2022] [Accepted: 04/19/2022] [Indexed: 02/01/2023] Open
Abstract
Microalgae have been increasingly considered as a sustainable “biofactory” with huge potentials to fill up the current and future shortages of food and nutrition. They have become an economically and technologically viable solution to produce a great diversity of high-value bioactive compounds, including n-3 polyunsaturated fatty acids (PUFA). The n-3 PUFA, especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), possess an array of biological activities and positively affect a number of diseases, including cardiovascular and neurodegenerative disorders. As such, the global market of n-3 PUFA has been increasing at a fast pace in the past two decades. Nowadays, the supply of n-3 PUFA is facing serious challenges as a result of global warming and maximal/over marine fisheries catches. Although increasing rapidly in recent years, aquaculture as an alternative source of n-3 PUFA appears insufficient to meet the fast increase in consumption and market demand. Therefore, the cultivation of microalgae stands out as a potential solution to meet the shortages of the n-3 PUFA market and provides unique fatty acids for the special groups of the population. This review focuses on the biosynthesis pathways and recombinant engineering approaches that can be used to enhance the production of n-3 PUFA, the impact of environmental conditions in heterotrophic cultivation on n-3 PUFA production, and the technologies that have been applied in the food industry to extract and purify oil in microalgae and protect n-3 PUFA from oxidation.
Collapse
Affiliation(s)
- Xiang Ren
- INNOBIO Corporation Limited, No. 49, DDA, Dalian 116600, China; (Y.L.); (C.F.); (H.H.); (W.W.)
- Correspondence: (X.R.); (Y.W.); Tel.: +86-411-65864645 (X.R.); +1-902-566-7953 (Y.W.)
| | - Yanjun Liu
- INNOBIO Corporation Limited, No. 49, DDA, Dalian 116600, China; (Y.L.); (C.F.); (H.H.); (W.W.)
| | - Chao Fan
- INNOBIO Corporation Limited, No. 49, DDA, Dalian 116600, China; (Y.L.); (C.F.); (H.H.); (W.W.)
| | - Hao Hong
- INNOBIO Corporation Limited, No. 49, DDA, Dalian 116600, China; (Y.L.); (C.F.); (H.H.); (W.W.)
| | - Wenzhong Wu
- INNOBIO Corporation Limited, No. 49, DDA, Dalian 116600, China; (Y.L.); (C.F.); (H.H.); (W.W.)
| | - Wei Zhang
- DeOxiTech Consulting, 30 Cloverfield Court, Dartmouth, NS B2W 0B3, Canada;
| | - Yanwen Wang
- Aquatic and Crop Resource Development Research Centre, National Research Council of Canada, 550 University Avenue, Charlottetown, PE C1A 4P3, Canada
- Correspondence: (X.R.); (Y.W.); Tel.: +86-411-65864645 (X.R.); +1-902-566-7953 (Y.W.)
| |
Collapse
|
6
|
Tipduangta P, Belton P, McAuley WJ, Qi S. The use of polymer blends to improve stability and performance of electrospun solid dispersions: The role of miscibility and phase separation. Int J Pharm 2021; 602:120637. [PMID: 33901595 DOI: 10.1016/j.ijpharm.2021.120637] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2021] [Revised: 04/19/2021] [Accepted: 04/20/2021] [Indexed: 02/06/2023]
Abstract
Solid dispersion-based nanofiber formulations of poorly soluble drugs prepared by electrospinning (ES) with a water-soluble polymer, can offer significant improvements in drug dissolution for oral drug administration. However, when hygroscopic polymers, such as polyvinylpyrrolidone (PVP) are used, environmental moisture sorption can lead to poor physical stability on storage. This study investigated the use of polymer blends to modify PVP-based ES formulations of a model poorly soluble drug, fenofibrate (FF), to improve its physical stability without compromising dissolution enhancement. FF-PVP ES dispersions demonstrated clear dissolution enhancement, but poor storage stability against high humidity. Polymer blends of PVP with Eudragit E, Soluplus and hypromellose acetate succinate (HPMCAS), were selected because of the low intrinsic moisture sorption of these polymers. The drug-polymer and polymer-polymer miscibility study revealed that FF was more miscible with Eudragit E and Soluplus than with PVP and HPMCAS, and that PVP was more miscible with HPMCAS than Eudragit E and Soluplus. This led to different configurations of phase separation in the placebo and drug-loaded fibres. The in vitro drug release data confirmed that the use of PVP-Eudragit E retained the dissolution enhancement of the PVP formulation, whereas PVP-Soluplus reduced the drug release rate in comparison to FF-PVP formulations. The moisture sorption results confirmed that moisture uptake by the polymer blends was reduced, but formulation deformation occurred to phase-separated blend formulations. The data revealed the importance of miscibility and phase separation in understanding the physical stability of the ES fibre mats. The findings provide insight into the design of formulations that can provide dissolution enhancement balanced with improved storage stability.
Collapse
Affiliation(s)
- Pratchaya Tipduangta
- School of Pharmacy, University of East Anglia, Norwich, Norfolk NR4 7TJ, UK; Department of Pharmaceutical Science, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand
| | - Peter Belton
- School of Chemistry, University of East Anglia, Norwich, Norfolk NR4 7TJ, UK
| | - William J McAuley
- Centre for Research in Topical Drug Delivery and Toxicology, School of Life and Medical Sciences, University of Hertfordshire, College Lane, Hatfield AL10 9AB, UK
| | - Sheng Qi
- School of Pharmacy, University of East Anglia, Norwich, Norfolk NR4 7TJ, UK.
| |
Collapse
|
7
|
Azizoğlu E, Özer Ö. Fabrication of Montelukast sodium loaded filaments and 3D printing transdermal patches onto packaging material. Int J Pharm 2020; 587:119588. [PMID: 32663585 DOI: 10.1016/j.ijpharm.2020.119588] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2020] [Revised: 06/23/2020] [Accepted: 06/24/2020] [Indexed: 01/16/2023]
Abstract
The main objectives of this work were to develop and characterize new 3D printing filaments and print them directly onto a packaging material. Different blends of polymers were tested to achieve low-temperature printing filaments, which are flexible and durable to be wound onto spools. The mechanical properties of filaments were compared with commercial filaments and evaluated by bending tests. Kollidon 12PF, PEG 4000, and PEO 900k blends resulted in promising filaments that could be extruded at 70 °C and had flexibility similar to commercial PLA filaments. Montelukast sodium (MS), which undergoes hepatic first-pass metabolism, was compounded into polymer blends, and drug-loaded filaments were extruded. All filaments were tested with a 3D printing pen prior to using with the 3D printer for transdermal patches. MS loaded filaments and patches showed similar flexibility with placebo. In vitro drug release studies showed 52% of MS was released in 24 h. Printing on disposable packaging material is presented for the first time with this study. Build plate adhesion and cohesion of 3D printed layers were successfully achieved. This new technique could prevent cross-contamination, save time, and provide ease of use, which can take us one step closer to the production of personalized drugs in pharmacies.
Collapse
Affiliation(s)
- Erkan Azizoğlu
- Ege University, Faculty of Pharmacy, Department of Pharmaceutical Technology, 35040 Bornova, Izmir, Turkey.
| | - Özgen Özer
- Ege University, Faculty of Pharmacy, Department of Pharmaceutical Technology, 35040 Bornova, Izmir, Turkey.
| |
Collapse
|
8
|
Amorphous multi-system of celecoxib improves its anti-inflammatory activity in vitro and oral absorption in rats. Int J Pharm 2019; 555:135-145. [DOI: 10.1016/j.ijpharm.2018.11.050] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2018] [Revised: 11/04/2018] [Accepted: 11/17/2018] [Indexed: 01/19/2023]
|
9
|
Kempin W, Domsta V, Grathoff G, Brecht I, Semmling B, Tillmann S, Weitschies W, Seidlitz A. Immediate Release 3D-Printed Tablets Produced Via Fused Deposition Modeling of a Thermo-Sensitive Drug. Pharm Res 2018; 35:124. [PMID: 29679157 DOI: 10.1007/s11095-018-2405-6] [Citation(s) in RCA: 98] [Impact Index Per Article: 16.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2017] [Accepted: 04/06/2018] [Indexed: 10/17/2022]
Abstract
PURPOSE Dissolution speeds of tablets printed via Fused Deposition Modeling (FDM) so far are significantly lower compared to powder or granule pressed immediate release tablets. The aim of this work was to print an actual immediate release tablet by choosing suitable polymers and printing designs, also taking into account lower processing temperatures (below 100°C) owing to the used model drug pantoprazole sodium. METHODS Five different pharmaceutical grade polymers polyvinylpyrrolidone (PVP K12), polyethylene glycol 6000 (PEG 6000), Kollidon® VA64, polyethylene glycol 20,000 (PEG 20,000) and poloxamer 407 were successfully hot-melt-extruded to drug loaded filaments and printed to tablets at the required low temperatures. RESULTS Tablets with the polymers PEG 6000 and PVP K12 and with a proportion of 10% pantoprazole sodium (w/w) demonstrated a fast drug release that was completed within 29 min or 10 min, respectively. By reducing the infill rate of PVP tablets to 50% and thereby increase the tablet porosity it was even possible to reduce the mean time for total drug release to only 3 min. CONCLUSIONS The knowledge acquired through this work might be very beneficial for future FDM applications in the field of immediate release tablets especially with respect to thermo-sensitive drugs.
Collapse
Affiliation(s)
- Wiebke Kempin
- Institute of Pharmacy, Center of Drug Absorption and Transport, University of Greifswald, Felix-Hausdorff-Straße 3, 17487, Greifswald, Germany
| | - Vanessa Domsta
- Institute of Pharmacy, Center of Drug Absorption and Transport, University of Greifswald, Felix-Hausdorff-Straße 3, 17487, Greifswald, Germany
| | - Georg Grathoff
- Economic geology and mineralogy, University of Greifswald, 17487, Greifswald, Germany
| | - Iris Brecht
- Plant Oranienburg, Takeda GmbH, 16515, Oranienburg, Germany
| | | | - Susan Tillmann
- Takeda Pharmaceuticals International AG Zürich, 8152, Glattpark, Switzerland
| | - Werner Weitschies
- Institute of Pharmacy, Center of Drug Absorption and Transport, University of Greifswald, Felix-Hausdorff-Straße 3, 17487, Greifswald, Germany
| | - Anne Seidlitz
- Institute of Pharmacy, Center of Drug Absorption and Transport, University of Greifswald, Felix-Hausdorff-Straße 3, 17487, Greifswald, Germany.
| |
Collapse
|
10
|
Pawar J, Narkhede R, Amin P, Tawde V. Design and Evaluation of Topical Diclofenac Sodium Gel Using Hot Melt Extrusion Technology as a Continuous Manufacturing Process with Kolliphor® P407. AAPS PharmSciTech 2017; 18:2303-2315. [PMID: 28108974 DOI: 10.1208/s12249-017-0713-5] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2016] [Accepted: 01/03/2017] [Indexed: 01/01/2023] Open
Abstract
The aim of the present context was to develop and evaluate a Kolliphor® P407-based transdermal gel formulation of diclofenac sodium by hot melt extrusion (HME) technology; central composite design was used to optimize the formulation process. In this study, we have explored first time ever HME as an industrially feasible and continuous manufacturing technology for the manufacturing of gel formulation using Kolliphor® P407 and Kollisolv® PEG400 as a gel base. Diclofenac sodium was used as a model drug. The HME parameters such as feeding rate, screw speed, and barrel temperature were crucial for the semisolid product development, and were optimized after preliminary trials. For the processing of the gel formulation by HME, a modified screw design was used to obtain a uniform product. The obtained product was evaluated for physicochemical characterization such as differential scanning calorimetry (DSC), X-ray diffraction (XRD), pH measurement, rheology, surface tension, and texture profile analysis. Moreover, it was analyzed for general appearance, spreadibility, surface morphology, and drug content. The optimized gel formulation showed homogeneity and transparent film when applied on a glass slide under microscope, pH was 7.02 and uniform drug content of 100.04 ± 2.74 (SD = 3). The DSC and XRD analysis of the HME gel formulation showed complete melting of crystalline API into an amorphous form. The Kolliphor® P407 and Kollisolv® PEG400 formed excellent gel formulation using HME with consistent viscoelastic properties of the product. An improved drug release was found for the HME gel, which showed a 100% drug release than that of a marketed product which showed only 88% of drug release at the end of 12 h. The Flux value of the HME gel was 106 than that of a marketed formulation, which showed only about 60 value, inferring a significant difference (P < 0.05) at the end of 1 h. This study demonstrates a novel application of the hot melt extrusion process for manufacturing of topical semisolid products.
Collapse
|
11
|
A Novel Approach for the Development of a Nanostructured Lipid Carrier Formulation by Hot-Melt Extrusion Technology. J Pharm Sci 2017; 106:1085-1091. [DOI: 10.1016/j.xphs.2016.12.015] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2016] [Revised: 12/09/2016] [Accepted: 12/14/2016] [Indexed: 01/23/2023]
|
12
|
Park JB, Lee BJ, Kang CY, Repka MA. Process Analytical Quality Control of Tailored Drug Release Formulation Prepared via Hot-Melt Extrusion Technology. J Drug Deliv Sci Technol 2017; 38:51-58. [PMID: 29312469 DOI: 10.1016/j.jddst.2017.01.007] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
The objective of the present study was to compare the influence of Eudragit® RS PO and RL PO blends on the release of water-soluble and insoluble drugs from hot-melt extruded formulations. In addition, we aimed to evaluate drug content uniformity and distribution by Fourier transform-infrared (FT-IR) chemical imaging. Theophylline (TP) and carbamazepine (CBZ) were selected as the water-soluble and insoluble model drugs, respectively. Eudragit® RS PO and RL PO were selected as the polymeric matrices. FT-IR chemical imaging clearly demonstrated the content uniformity and distribution for both drugs in the extrudates, which was confirmed by HPLC. Increasing the ratio of Eudragit® RL PO led to an increase in the in vitro drug release, whereas an increase in the ratio of Eudragit® RS PO sustained the drug release for up to 12 h. The hot-melt extrusion of TP and CBZ with varying ratios of Eudragit® RS PO and RL PO can be employed to tailor the drug release profiles. In this study, we demonstrated, for the first time, the use of FT-IR chemical imaging as a process analytical technique to determine the drug content uniformity and distribution. Our data correlated well with the results of HPLC analysis in the study of tailored drug release from the prepared hot-melt extruded formulation.
Collapse
Affiliation(s)
- Jun-Bom Park
- College of Pharmacy, Sahmyook University, Seoul, Republic of Korea
| | - Beom-Jin Lee
- College of Pharmacy, Ajou University, Suwon, Republic of Korea
| | - Chin-Yang Kang
- College of Pharmacy, Sahmyook University, Seoul, Republic of Korea
| | - Michael A Repka
- Department of Pharmaceutics & Drug Delivery, University of Mississippi, University, MS, USA.,Pii Center for Pharmaceutical Technology, School of Pharmacy, University of Mississippi, University, MS, USA
| |
Collapse
|
13
|
Alsulays BB, Kulkarni V, Alshehri SM, Almutairy BK, Ashour EA, Morott JT, Alshetaili AS, Park JB, Tiwari RV, Repka MA. Preparation and evaluation of enteric coated tablets of hot-melt extruded lansoprazole. Drug Dev Ind Pharm 2016; 43:789-796. [PMID: 27486807 DOI: 10.1080/03639045.2016.1220567] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
The objective of this work was to use hot-melt extrusion (HME) technology to improve the physiochemical properties of lansoprazole (LNS) to prepare stable enteric coated LNS tablets. For the extrusion process, we chose Kollidon® 12 PF (K12) polymeric matrix. Lutrol® F 68 was selected as the plasticizer and magnesium oxide (MgO) as the alkalizer. With or without the alkalizer, LNS at 10% drug load was extruded with K12 and F68. LNS changed to the amorphous phase and showed better release compared to that of the pure crystalline drug. Inclusion of MgO improved LNS extrudability and release and resulted in over 80% drug release in the buffer stage. Hot-melt extruded LNS was physically and chemically stable after 12 months of storage. Both formulations were studied for compatibility with Eudragit® L100-55. The optimized formulation was compressed into a tablet followed by coating process utilizing a pan coater using L100-55 as an enteric coating polymer. In a two-step dissolution study, the release profile of the enteric coated LNS tablets in the acidic stage was less than 10% of the LNS, while that in the buffer stage was more than 80%. Drug content analysis revealed the LNS content to be 97%, indicating the chemical stability of the enteric coated tablet after storage for six months. HME, which has not been previously used for LNS, is a valuable technique to reduce processing time in the manufacture of enteric coated formulations of an acid-sensitive active pharmaceutical ingredient as compared to the existing methods.
Collapse
Affiliation(s)
- Bader B Alsulays
- a Department of Pharmaceutics and Drug Delivery, School of Pharmacy , The University of Mississippi , Oxford , MS , USA.,b Department of Pharmaceutics, College of Pharmacy , Prince Sattam Bin Abdulaziz University , Alkharj , Saudi Arabia
| | - Vijay Kulkarni
- a Department of Pharmaceutics and Drug Delivery, School of Pharmacy , The University of Mississippi , Oxford , MS , USA
| | - Sultan M Alshehri
- c Department of Pharmaceutics, College of Pharmacy , King Saud University , Riyadh , Saudi Arabia
| | - Bjad K Almutairy
- a Department of Pharmaceutics and Drug Delivery, School of Pharmacy , The University of Mississippi , Oxford , MS , USA
| | - Eman A Ashour
- a Department of Pharmaceutics and Drug Delivery, School of Pharmacy , The University of Mississippi , Oxford , MS , USA
| | - Joseph T Morott
- a Department of Pharmaceutics and Drug Delivery, School of Pharmacy , The University of Mississippi , Oxford , MS , USA
| | - Abdullah S Alshetaili
- b Department of Pharmaceutics, College of Pharmacy , Prince Sattam Bin Abdulaziz University , Alkharj , Saudi Arabia
| | - Jun-Bom Park
- a Department of Pharmaceutics and Drug Delivery, School of Pharmacy , The University of Mississippi , Oxford , MS , USA
| | - Roshan V Tiwari
- a Department of Pharmaceutics and Drug Delivery, School of Pharmacy , The University of Mississippi , Oxford , MS , USA
| | - Michael A Repka
- a Department of Pharmaceutics and Drug Delivery, School of Pharmacy , The University of Mississippi , Oxford , MS , USA.,d Pii Center for Pharmaceutical Technology, School of Pharmacy , The University of Mississippi , Oxford , MS , USA
| |
Collapse
|
14
|
Okwuosa TC, Stefaniak D, Arafat B, Isreb A, Wan KW, Alhnan MA. A Lower Temperature FDM 3D Printing for the Manufacture of Patient-Specific Immediate Release Tablets. Pharm Res 2016; 33:2704-12. [PMID: 27506424 DOI: 10.1007/s11095-016-1995-0] [Citation(s) in RCA: 164] [Impact Index Per Article: 20.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2016] [Accepted: 07/07/2016] [Indexed: 11/25/2022]
Abstract
PURPOSE The fabrication of ready-to-use immediate release tablets via 3D printing provides a powerful tool to on-demand individualization of dosage form. This work aims to adapt a widely used pharmaceutical grade polymer, polyvinylpyrrolidone (PVP), for instant on-demand production of immediate release tablets via FDM 3D printing. METHODS Dipyridamole or theophylline loaded filaments were produced via processing a physical mixture of API (10%) and PVP in the presence of plasticizer through hot-melt extrusion (HME). Computer software was utilized to design a caplet-shaped tablet. The surface morphology of the printed tablet was assessed using scanning electron microscopy (SEM). The physical form of the drugs and its integrity following an FDM 3D printing were assessed using x-ray powder diffractometry (XRPD), thermal analysis and HPLC. In vitro drug release studies for all 3D printed tablets were conducted in a USP II dissolution apparatus. RESULTS Bridging 3D printing process with HME in the presence of a thermostable filler, talc, enabled the fabrication of immediate release tablets at temperatures as low as 110°C. The integrity of two model drugs was maintained following HME and FDM 3D printing. XRPD indicated that a portion of the loaded theophylline remained crystalline in the tablet. The fabricated tablets demonstrated excellent mechanical properties, acceptable in-batch variability and an immediate in vitro release pattern. CONCLUSIONS Combining the advantages of PVP as an impeding polymer with FDM 3D printing at low temperatures, this approach holds a potential in expanding the spectrum of drugs that could be used in FDM 3D printing for on demand manufacturing of individualised dosage forms.
Collapse
Affiliation(s)
- Tochukwu C Okwuosa
- School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston, Lancashire, UK
| | - Dominika Stefaniak
- School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston, Lancashire, UK
| | - Basel Arafat
- School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston, Lancashire, UK
| | - Abdullah Isreb
- School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston, Lancashire, UK
| | - Ka-Wai Wan
- School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston, Lancashire, UK
| | - Mohamed A Alhnan
- School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston, Lancashire, UK.
| |
Collapse
|
15
|
Alshehri SM, Tiwari RV, Alsulays BB, Ashour EA, Alshetaili AS, Almutairy B, Park JB, Morott J, Sandhu B, Majumdar S, Repka MA. Investigation of the combined effect of MgO and PEG on the release profile of mefenamic acid prepared via hot-melt extrusion techniques. Pharm Dev Technol 2016; 22:740-753. [PMID: 26821841 DOI: 10.3109/10837450.2016.1138129] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
This study aimed to investigate the combined effect of magnesium oxide (MgO) as an alkalizer and polyethylene glycol (PEG) as a plasticizer and wetting agent in the presence of Kollidon® 12 PF and 17 PF polymer carriers on the release profile of mefenamic acid (MA), which was prepared via hot-melt extrusion technique. Various drug loads of MA and various ratios of the polymers, PEG 3350 and MgO were blended using a V-shell blender and extruded using a twin-screw extruder (16-mm Prism EuroLab, ThermoFisher Scientific, Carlsbad, CA) at different screw speeds and temperatures to prepare a solid dispersion system. Differential scanning calorimetry and X-ray diffraction data of the extruded material confirmed that the drug existed in the amorphous form, as evidenced by the absence of corresponding peaks. MgO and PEG altered the micro-environmental pH to be more alkaline (pH 9) and increased the hydrophilicity and dispersibility of the extrudates to enhance MA solubility and release, respectively. The in vitro release study demonstrated an immediate release for 2 h with more than 80% drug release within 45 min in matrices containing MgO and PEG in combination with polyvinylpyrrolidone when compared to the binary mixture, physical mixture and pure drug.
Collapse
Affiliation(s)
- Sultan M Alshehri
- a Department of Pharmaceutics and Drug Delivery , School of Pharmacy, The University of Mississippi, University , MS , USA
| | - Roshan V Tiwari
- a Department of Pharmaceutics and Drug Delivery , School of Pharmacy, The University of Mississippi, University , MS , USA
| | - Bader B Alsulays
- b Department of Pharmaceutics , College of Pharmacy, Prince Sattam Bin Abdulaziz University , Alkharj , Saudi Arabia
| | - Eman A Ashour
- a Department of Pharmaceutics and Drug Delivery , School of Pharmacy, The University of Mississippi, University , MS , USA
| | - Abdullah S Alshetaili
- b Department of Pharmaceutics , College of Pharmacy, Prince Sattam Bin Abdulaziz University , Alkharj , Saudi Arabia
| | - Bjad Almutairy
- a Department of Pharmaceutics and Drug Delivery , School of Pharmacy, The University of Mississippi, University , MS , USA
| | - Jun-Bom Park
- c College of Pharmacy, Sahm Yook University , Seoul , Korea
| | - Joseph Morott
- a Department of Pharmaceutics and Drug Delivery , School of Pharmacy, The University of Mississippi, University , MS , USA
| | - Bhupinder Sandhu
- d Department of Chemistry , Kansas State University , Manhattan , KS , USA , and
| | - Soumyajit Majumdar
- a Department of Pharmaceutics and Drug Delivery , School of Pharmacy, The University of Mississippi, University , MS , USA
| | - Michael A Repka
- a Department of Pharmaceutics and Drug Delivery , School of Pharmacy, The University of Mississippi, University , MS , USA.,e Pii Center for Pharmaceutical Technology, School of Pharmacy, The University of Mississippi, University , MS , USA
| |
Collapse
|